WordNet

an abnormal new mass of tissue that serves no purpose (同)tumour, neoplasm
the pathological process that results in the formation and growth of a tumor
indicates continuity or persistence or concentration; "his spirit lives on"; "shall I read on?"
(of events) planned or scheduled; "the picnic is on, rain or shine"; "we have nothing on for Friday night"
in a state required for something to function or be effective; "turn the lights on"; "get a load on"
in operation or operational; "left the oven on"; "the switch is in the on position"

PrepTutorEJDIC

(体内にできる)新生物;腫瘍(しゅよう)
下士官[noncommissioned officerの短縮形]
(また《文》upon)《位置・場所》…『の上に』,の上で,の上の / (また《文》upon)《運動・動作の方向・対象》…『に』[向かって] / 《話》…を身につけて / (また《文》upon)《近接して場所》…の近くに,…に面して,…の側に / 《特定の日時》…『に』 / 《状態》…『して』,…中で,…すると / (また《文》upon)…『について』,…に関して / 《目的》…『で』,…に / (また《文》upon)…に基づいて,…によって,…の支え(助け)で / 《所属を表して》(委員会・チームなどの)一員で / (また《文》upon)…を軸にして,…で / (また《文》upon)《前後に同じ名詞を並べて》…に加えて,…についで / 『上に』,『身につけて』 / (電気・水道・ガス・ラジオなどが)『ついて』,通じて / 行われて,続けて,従事して / 《時の副詞[句]を伴って》前方へ,ずっと

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人癌患者における静脈血栓塞栓症のリスクおよび予防 risk and prevention of venous thromboembolism in adults with cancer
2. 蛍光気管支鏡検査 fluorescence bronchoscopy

English Journal

New drugs and targeted treatments in Hodgkin's lymphoma.

Provencio M1, Sánchez A2, Sánchez-Beato M2.Author information 1Medical Oncology Service, Onco-hematology Research Unit, Instituto de Investigación Sanitaria Puerta de Hierro, Hospital Universitario Puerta de Hierro-Majadahonda, Spain. Electronic address: mprovenciop@gmail.com.2Medical Oncology Service, Onco-hematology Research Unit, Instituto de Investigación Sanitaria Puerta de Hierro, Hospital Universitario Puerta de Hierro-Majadahonda, Spain.AbstractNew drugs are being developed in recent years that may change the handling of relapsed and refractory Hodgkin's lymphoma patients. Brentuximab vedotin treatment has already been approved by the FDA; and other drugs are promising, such as histone deacetylase inhibitors, bendamustine, lenalidomide and m-TOR inhibitors.
Cancer treatment reviews.Cancer Treat Rev.2014 Apr;40(3):457-64. doi: 10.1016/j.ctrv.2013.09.005. Epub 2013 Sep 20.
New drugs are being developed in recent years that may change the handling of relapsed and refractory Hodgkin's lymphoma patients. Brentuximab vedotin treatment has already been approved by the FDA; and other drugs are promising, such as histone deacetylase inhibitors, bendamustine, lenalidomide and
PMID 24095205

Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy.

Vlatković N, Boyd MT, Rubbi CP.Author information Cancer Research Centre, University of Liverpool, 200 London Rd, Liverpool, L3 9TA, UK.AbstractNucleoli perform a crucial cell function, ribosome biogenesis, and of critical relevance to the subject of this review, they are also extremely sensitive to cellular stresses, which can cause loss of function and/or associated structural disruption. In recent years, we have learned that cells take advantage of this stress sensitivity of nucleoli, using them as stress sensors. One major protein regulated by this role of nucleoli is the tumor suppressor p53, which is activated in response to diverse cellular injuries in order to exert its onco-protective effects. Here we discuss a model of nucleolar regulation of p53, which proposes that key steps in the promotion of p53 degradation by the ubiquitin ligase MDM2 occur in nucleoli, thus providing an explanation for the observed link between nucleolar disruption and p53 stability. We review current evidence for this compartmentalization in p53 homeostasis and highlight current limitations of the model. Interestingly, a number of current chemotherapeutic agents capable of inducing a p53 response are likely to do so by targeting nucleolar functions and these compounds may serve to inform further improved therapeutic targeting of nucleoli.
Cellular and molecular life sciences : CMLS.Cell Mol Life Sci.2014 Mar;71(5):771-91. doi: 10.1007/s00018-013-1361-x. Epub 2013 May 18.
Nucleoli perform a crucial cell function, ribosome biogenesis, and of critical relevance to the subject of this review, they are also extremely sensitive to cellular stresses, which can cause loss of function and/or associated structural disruption. In recent years, we have learned that cells take a
PMID 23685903

The Edmonton Symptom Assessment System (ESAS) as a screening tool for depression and anxiety in non-advanced patients with solid or haematological malignancies on cure or follow-up.

Ripamonti CI, Bandieri E, Pessi MA, Maruelli A, Buonaccorso L, Miccinesi G.Author information Department of Hematology and Pediatric Onco-Hematology, Supportive Care in Cancer Unit, Fondazione IRCCS, Istituto Nazionale dei Tumori, Via Venezian, 1, 20133, Milan, Italy, carla.ripamonti@istitutotumori.mi.it.AbstractBACKGROUND: Symptoms' assessment should be considered a clinical practice routine in all cancer stages. The Edmonton Symptom Assessment System (ESAS) is a ten-item patient-rated symptom assessment developed and validated for population affected by cancer in different languages and cultures. The main objective of this study was to assess the performance of ESAS items on anxiety and depression when detecting Hospital Anxiety Depression Scale (HADS) 'cases'.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.Support Care Cancer.2014 Mar;22(3):783-93. doi: 10.1007/s00520-013-2034-x. Epub 2013 Nov 26.
BACKGROUND: Symptoms' assessment should be considered a clinical practice routine in all cancer stages. The Edmonton Symptom Assessment System (ESAS) is a ten-item patient-rated symptom assessment developed and validated for population affected by cancer in different languages and cultures. The main
PMID 24276952